alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
In The

Court of Appeals

Sixth Appellate District of Texas at Texarkana

______________________________

No. 06-11-00122-CR

______________________________

VINSON LARRY BRUCE, Appellant

V.

THE STATE OF TEXAS, Appellee

 

On Appeal from the 102nd Judicial District Court

Bowie County, Texas

Trial Court No. 09F0385-102

 

Before Morriss, C.J., Carter and Moseley, JJ.

Memorandum Opinion by Chief Justice Morriss
2

MEMORANDUM OPINION

Vinson Larry Bruce has filed pro se a notice of appeal from his conviction of aggravated 

robbery. On our review of the clerk’s record, we noted that the trial court’s certification of right 

of appeal stated that this was a plea agreement case and that Bruce has no right of appeal. 

Unless a certification, showing that a defendant has the right of appeal, is in the record, we 

must dismiss the appeal. See TEX. R. APP. P. 25.2(d). 

Because the trial court’s certification affirmatively shows Bruce has no right of appeal, and 

because the record before us does not reflect that the certification is incorrect, see Dears v. State, 

154 S.W.3d 610, 615 (Tex. Crim. App. 2005), we must dismiss the appeal.

We dismiss the appeal for want of jurisdiction. 

Josh R. Morriss, III

Chief Justice

Date Submitted: July 18, 2011

Date Decided: July 19, 2011

Do Not Publish
<TABLE> <S> <C>

<ARTICLE> 9
<MULTIPLIER>   1,000
       
<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          SEP-30-1997
<PERIOD-END>                               SEP-30-1997
<CASH>                                           1,343
<INT-BEARING-DEPOSITS>                           4,954
<FED-FUNDS-SOLD>                                     0
<TRADING-ASSETS>                                     0
<INVESTMENTS-HELD-FOR-SALE>                     69,426
<INVESTMENTS-CARRYING>                           6,994
<INVESTMENTS-MARKET>                             7,071
<LOANS>                                        289,908
<ALLOWANCE>                                      2,258
<TOTAL-ASSETS>                                 387,032
<DEPOSITS>                                     275,980
<SHORT-TERM>                                    50,045
<LIABILITIES-OTHER>                              2,318
<LONG-TERM>                                        272
<PREFERRED-MANDATORY>                              437
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                      57,981
<TOTAL-LIABILITIES-AND-EQUITY>                 387,032
<INTEREST-LOAN>                                 24,247
<INTEREST-INVEST>                                5,215
<INTEREST-OTHER>                                   174
<INTEREST-TOTAL>                                29,636
<INTEREST-DEPOSIT>                              12,378
<INTEREST-EXPENSE>                              15,724
<INTEREST-INCOME-NET>                           13,912
<LOAN-LOSSES>                                      321
<SECURITIES-GAINS>                                 384
<EXPENSE-OTHER>                                  8,502
<INCOME-PRETAX>                                  9,095
<INCOME-PRE-EXTRAORDINARY>                       9,095
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     5,438
<EPS-PRIMARY>                                     1.28
<EPS-DILUTED>                                     1.27
<YIELD-ACTUAL>                                    8.05
<LOANS-NON>                                      1,497
<LOANS-PAST>                                         0
<LOANS-TROUBLED>                                     0
<LOANS-PROBLEM>                                      0
<ALLOWANCE-OPEN>                                 2,419
<CHARGE-OFFS>                                      829
<RECOVERIES>                                       157
<ALLOWANCE-CLOSE>                                2,258
<ALLOWANCE-DOMESTIC>                               359
<ALLOWANCE-FOREIGN>                                  0
<ALLOWANCE-UNALLOCATED>                          1,899
         

</TABLE>
<PAGE>   1

                                  EXHIBIT 23.1


               CONSENT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS


We hereby consent to the incorporation by reference in the Prospectus
constituting part of this Registration Statement on Form S-3 of our report dated
February 17, 1998, appearing on page F-2 of Data Dimensions, Inc. Annual Report
on Form 10-K for the year ended December 31, 1998. We also consent to the
reference to our firm under the heading "EXPERTS" in such Prospectus.

BDO Seidman, LLP


/s/ BDO Seidman, LLP
-------------------------------
Seattle, Washington
March 9, 1999



                                     III-3
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONDENSED CONSOLIDATED BALANCE SHEET OF DICTAPHONE CORPORATION AT DECEMBER 31,
1996, AND THE CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS FOR THE YEAR ENDED
DECEMBER 31, 1996, AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH
FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-START>                             JAN-01-1996
<PERIOD-END>                               DEC-31-1996
<CASH>                                           7,927
<SECURITIES>                                         0
<RECEIVABLES>                                   55,040
<ALLOWANCES>                                     1,339
<INVENTORY>                                     56,840
<CURRENT-ASSETS>                               128,301
<PP&E>                                          61,773
<DEPRECIATION>                                  24,765
<TOTAL-ASSETS>                                 504,835
<CURRENT-LIABILITIES>                           95,257
<BONDS>                                        340,086
<PREFERRED-MANDATORY>                           18,142
<PREFERRED>                                          0
<COMMON>                                            95
<OTHER-SE>                                      41,141
<TOTAL-LIABILITY-AND-EQUITY>                   504,835
<SALES>                                        239,638
<TOTAL-REVENUES>                               332,468
<CGS>                                          126,734
<TOTAL-COSTS>                                  344,500
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              42,897
<INCOME-PRETAX>                               (53,591)
<INCOME-TAX>                                    18,931
<INCOME-CONTINUING>                           (34,660)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (34,660)
<EPS-PRIMARY>                                   (3.90)
<EPS-DILUTED>                                   (3.90)


</TABLE>
§ 640.53 Testing the blood. ( a ) Blood from which plasma is separated for the preparation of Cryoprecipitated AHF shall be tested as prescribed in § 610.40 of this chapter and § 640.5 (b) and (c).
( b ) The tests shall be performed on a sample of blood collected at the time of collecting the source blood, and such sample container shall be labeled with the donor's number before the container is filled.
( c ) Manufacturers of Cryoprecipitated AHF obtained from plasma collected by plasmapheresis shall have testing and record-keeping responsibilities equivalent to those prescribed in §§ 640.71 and 640.72.
[42 FR 21774, Apr. 29, 1977, as amended at 42 FR 37546, July 22, 1977; 42 FR 43063, Aug. 26, 1977; 50 FR 4139, Jan. 29, 1985; 53 FR 117, Jan. 5, 1988; 66 FR 31165, June 11, 2001; 80 FR 29905, May 22, 2015]
<TABLE> <S> <C>


<ARTICLE> 5
       
<S>                                       <C>
<PERIOD-TYPE>                             YEAR
<FISCAL-YEAR-END>                         DEC-31-1996
<PERIOD-END>                              DEC-31-1996
<CASH>                                         35,519
<SECURITIES>                                3,949,951
<RECEIVABLES>                                  81,242
<ALLOWANCES>                                        0
<INVENTORY>                                   786,415
<CURRENT-ASSETS>                            4,935,556
<PP&E>                                        628,664
<DEPRECIATION>                                133,801
<TOTAL-ASSETS>                              5,622,348
<CURRENT-LIABILITIES>                         824,848
<BONDS>                                             0
<PREFERRED-MANDATORY>                               0
<PREFERRED>                                        55
<COMMON>                                      140,464
<OTHER-SE>                                  4,642,580
<TOTAL-LIABILITY-AND-EQUITY>                5,622,348
<SALES>                                       327,803
<TOTAL-REVENUES>                              533,190
<CGS>                                         167,248
<TOTAL-COSTS>                               8,017,191
<OTHER-EXPENSES>                                    0
<LOSS-PROVISION>                                    0 
<INTEREST-EXPENSE>                             27,145
<INCOME-PRETAX>                            (8,122,116)
<INCOME-TAX>                                        0
<INCOME-CONTINUING>                                 0
<DISCONTINUED>                                      0
<EXTRAORDINARY>                                     0
<CHANGES>                                           0
<NET-INCOME>                               (8,122,116)
<EPS-PRIMARY>                                   (0.58)
<EPS-DILUTED>                                   (0.58)
        


</TABLE>
Editorial Note on Part 73
Editorial Note: Nomenclature changes to part 73 appear at 66 FR 66742, Dec. 27, 2001.

§ 73.2095 β-Carotene. ( a ) *Identity and specifications.* The color additive β-carotene shall conform in identity and specifications to the requirements of § 73.95(a)(1) and (b).
( b ) *Uses and restrictions.* The color additive β-carotene may be safely used in coloring cosmetics generally, including cosmetics intended for use in the area of the eye, in amounts consistent with good manufacturing practices.
( c ) *Labeling.* The color additive and any mixture prepared therefrom intended solely or in part for coloring purposes shall bear, in addition to any information required by law, labeling in accordance with the provisions of § 70.25 of this chapter.
( d ) *Exemption from certification.* Certification of this color additive is not necessary for the protection of the public health, and therefore batches therof are exempt from the certification pursuant to section 721(c) of the act.
[42 FR 33722, July 1, 1977]
EXHIBIT 32

CERTIFICATIONPURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Teachers Insurance and Annuity Association of America, do hereby certify, to such officers knowledge, that:

The annual report on Form 10-K of the TIAA Real Estate Account (the Account) for the year ended December 31, 2008 (the Form 10-K) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in the Form 10-K fairly presents, in
  all material respects, the financial condition and results of operations of the Account.

|                      |  |                                                                                                                              
|--------------------- |  | -----------------------------------------------------------------------------------------------------------------------------
|Dated: March 20, 2009 |  | /s/ Roger W. Ferguson, Jr.                                                                                                   
|                      |  | Roger W. Ferguson, Jr.President and Chief Executive Officer,Teachers Insurance and AnnuityAssociation of America             
|                      |  |                                                                                                                              
|Dated: March 20, 2009 |  | /s/ Georganne C. Proctor                                                                                                     
|                      |  | Georganne C. ProctorExecutive Vice President and Chief FinancialOfficer, Teachers Insurance and AnnuityAssociation of America

A signed original of this written statement required by Section 906 has been provided to the TIAA Real Estate Account and will be retained by the Account and furnished to the Securities and Exchange Commission or its staff upon request.

98



---
<TABLE> <S> <C>


<ARTICLE>                     5
<MULTIPLIER>                  1000

<S>                              <C>
<PERIOD-TYPE>                    3-MOS
<FISCAL-YEAR-END>                                   DEC-31-2000
<PERIOD-START>                                      JAN-01-2000
<PERIOD-END>                                        MAR-31-2000
<CASH>                                                       36
<SECURITIES>                                                  0
<RECEIVABLES>                                            37,723
<ALLOWANCES>                                              2,213
<INVENTORY>                                              32,989
<CURRENT-ASSETS>                                         71,122
<PP&E>                                                    5,292
<DEPRECIATION>                                            2,038
<TOTAL-ASSETS>                                           85,442
<CURRENT-LIABILITIES>                                    62,992
<BONDS>                                                    4684
<PREFERRED-MANDATORY>                                       334
<PREFERRED>                                                   0
<COMMON>                                                      0
<OTHER-SE>                                               17,432
<TOTAL-LIABILITY-AND-EQUITY>                             85,442
<SALES>                                                  43,369
<TOTAL-REVENUES>                                         43,369
<CGS>                                                    32,912
<TOTAL-COSTS>                                                 0
<OTHER-EXPENSES>                                         11,815
<LOSS-PROVISION>                                              0
<INTEREST-EXPENSE>                                          494
<INCOME-PRETAX>                                          (1,852)
<INCOME-TAX>                                               (696)
<INCOME-CONTINUING>                                      (1,156)
<DISCONTINUED>                                                0
<EXTRAORDINARY>                                               0
<CHANGES>                                                     0
<NET-INCOME>                                             (1,156)
<EPS-BASIC>                                               (0.38)
<EPS-DILUTED>                                             (0.34)



</TABLE>
Editorial Note on Part 312
Editorial Note: Nomenclature changes to part 312 appear at 69 FR 13717, Mar. 24, 2004.

§ 312.22 General principles of the IND submission. ( a ) FDA's primary objectives in reviewing an IND are, in all phases of the investigation, to assure the safety and rights of subjects, and, in Phase 2 and 3, to help assure that the quality of the scientific evaluation of drugs is adequate to permit an evaluation of the drug's effectiveness and safety. Therefore, although FDA's review of Phase 1 submissions will focus on assessing the safety of Phase 1 investigations, FDA's review of Phases 2 and 3 submissions will also include an assessment of the scientific quality of the clinical investigations and the likelihood that the investigations will yield data capable of meeting statutory standards for marketing approval.
( b ) The amount of information on a particular drug that must be submitted in an IND to assure the accomplishment of the objectives described in paragraph (a) of this section depends upon such factors as the novelty of the drug, the extent to which it has been studied previously, the known or suspected risks, and the developmental phase of the drug.
( c ) The central focus of the initial IND submission should be on the general investigational plan and the protocols for specific human studies. Subsequent amendments to the IND that contain new or revised protocols should build logically on previous submissions and should be supported by additional information, including the results of animal toxicology studies or other human studies as appropriate. Annual reports to the IND should serve as the focus for reporting the status of studies being conducted under the IND and should update the general investigational plan for the coming year.
( d ) The IND format set forth in § 312.23 should be followed routinely by sponsors in the interest of fostering an efficient review of applications. Sponsors are expected to exercise considerable discretion, however, regarding the content of information submitted in each section, depending upon the kind of drug being studied and the nature of the available information. Section 312.23 outlines the information needed for a commercially sponsored IND for a new molecular entity. A sponsor-investigator who uses, as a research tool, an investigational new drug that is already subject to a manufacturer's IND or marketing application should follow the same general format, but ordinarily may, if authorized by the manufacturer, refer to the manufacturer's IND or marketing application in providing the technical information supporting the proposed clinical investigation. A sponsor-investigator who uses an investigational drug not subject to a manufacturer's IND or marketing application is ordinarily required to submit all technical information supporting the IND, unless such information may be referenced from the scientific literature.
**Exhibit 10.19**

**ViroPharma Board Compensation Policy**

Directors that are non-executive officers of ViroPharma, and directors thatare not affiliated with a person or entity that has been granted a contractual right to appoint a director to the Board of Directors (“Eligible Directors”), shall receive a cash retainer of $25,000 annually. The Chairman of the Board, ifan independent director as set forth in requirements of the Nasdaq Stock Market, shall receive an additional annual retainer of $30,000. A lead independent director shall receive an additional annual retainer of $10,000. The Audit Committee Chairmanshall receive an additional annual retainer of $5,000. The Compensation Committee Chairman and Nominating and Governance Committee Chairman shall receive an additional annual retainer of $5,000. Eligible Directors shall receive $2,500 for each boardmeeting attended, provided that no payments shall be made for teleconferences lasting less than one (1) hour, and $1,000 for each committee meeting, plus travel expenses, for each board and committee meeting that they attend. 

Eligible Directors shall receive an option grant of 25,000 shares, vesting in equal increments over 3 years, upon his or her initial election to the Board. Thesedirectors also shall receive option grants once each year to purchase 15,000 shares of our common stock, vesting in full after one year from the date of grant. In a director’s initial year of service, he or she will be entitled to receive(1) the 25,000 share initial election grant, and (2) a pro-rata portion of the 15,000 share annual grant.
EXHIBIT 32.01 - SECTION 1350 CERTIFICATION
 

      I, Shaun  O'Brien,  the Chief  Financial  Officer of CIS  Investments,  Inc.  ("CISI"),  the General Partner ofIDS Managed Futures II, L.P.(the "Partnership"),  and I, James A.  Davison,  the  President and Chief Executive Officer of CISI,  certify that (i) the attached  10-Q fullycomplies with the  requirements  of Section 13(a) or 15(d) of the Securities  Exchange Act of 1934 and (ii) the informationcontained in the attached Form 10-Q fairly  presents,  in all material  respects,  the  financial  condition and results ofoperations of the Partnership.
 

 
James A. Davison               President and Chief Executive Officer               CIS Investments, Inc.               November 12, 2004 Shaun D. O'Brien               Chief Financial Officer               CIS Investments, Inc.               November 12, 2004
<TABLE> <S> <C>

<PAGE>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          APR-30-2000
<PERIOD-START>                             MAY-01-1999
<PERIOD-END>                               OCT-31-1999
<CASH>                                          28,538
<SECURITIES>                                         0
<RECEIVABLES>                                  662,753
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                               692,491
<PP&E>                                       6,821,010
<DEPRECIATION>                             (1,630,425)
<TOTAL-ASSETS>                               6,088,196
<CURRENT-LIABILITIES>                        1,867,552
<BONDS>                                      3,571,273
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                    24,169,536
<OTHER-SE>                                           0
<TOTAL-LIABILITY-AND-EQUITY>                 6,088,196
<SALES>                                              0
<TOTAL-REVENUES>                             1,319,020
<CGS>                                                0
<TOTAL-COSTS>                                  603,891
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             136,589
<INCOME-PRETAX>                                      0
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (694,696)
<EPS-BASIC>                                      (.11)
<EPS-DILUTED>                                    (.11)


</TABLE>
<PAGE>   1

                                                                    EXHIBIT 23.1

                       CONSENT OF INDEPENDENT ACCOUNTANTS

     We hereby consent to the incorporation by reference in this Registration
Statement on Form S-3 of our report dated March 31, 1999 relating to the
consolidated financial statements and financial statement schedules, which
appear in Getty Images, Inc.'s Annual Report on Form 10-K for the year ended
December 31, 1998. We also consent to the reference to us under the heading
"Experts" in such Registration Statement.

PricewaterhouseCoopers

PricewaterhouseCoopers
London, England
October 28, 1999